Microplate Luminometer Market to Reach USD 745 Million by 2031 Amid Surge in Cell-Based and Molecular Diagnostics

Unlock insights into the Global Microplate Luminometer Market with our comprehensive research report. Explore industry trends, technological innovations, key players, and market dynamics.

Chicago, 31th May 2025 — According to Clearview Market Insights (CVMI), the global microplate luminometer market is projected to grow from USD 421 million in 2024 to USD 745 million by 2031, with a robust CAGR of 8.2 percent. These instruments, essential for luminescence-based assays, are seeing increased adoption across drug discovery, oncology research, vaccine development, and high-throughput diagnostics.

Luminometers are becoming indispensable in labs working on ATP monitoring, gene reporter assays, and bioluminescent cell viability studies," said Dr. Victor Tran, Senior Analytical Devices Analyst at CVMI. "Increasing demand for real-time, ultra-sensitive detection is pushing both innovation and investment.

Request Sample @ https://clearviewmarketinsights.com/report-details/global-microplate-luminometer-market/

Market Highlights

Metric

2024

2031

CAGR (2024–2031)

Market Value (USD Million)

421

745

8.2 %

Academic & Research Use

34 %

31 %

Pharma & Biotech Use

37 %

39 %

Asia-Pacific CAGR

9.4 %

Key Growth Drivers

  • Rising Bioluminescent Assays – Luciferase-based detection systems are used extensively in molecular biology, particularly in gene expression and drug discovery.
  • Cell-Based Screening Demand – Oncology, immunology, and neuroscience labs increasingly favor luminescence for higher signal-to-noise ratios.
  • COVID-19 Legacy – Accelerated interest in compact luminometers for serological and vaccine R&D.
  • Automation Integration – Labs prefer instruments with robotic compatibility and plate stackers for high-throughput environments.
  • Compact Format Trends – Space-saving benchtop models gain popularity in decentralized diagnostics and academic labs.

Leading Companies

Company

2024 Share

Key Focus

Thermo Fisher Scientific

22 %

Varioskan™ LUX with extended dynamic range

Promega Corporation

19 %

GloMax® Discover and high-sensitivity substrate pairing

BMG LABTECH

15 %

CLARIOstar® Plus with dual monochromators

Tecan Group Ltd.

11 %

Infinite® series with modular software features

Berthold Technologies

8 %

NightSHADE LB 985 in vivo imaging integration

Regional Momentum

  • North America – Strongest demand from CROs and pharma labs; NIH and BARDA investments bolster device installs.
  • Europe – R&D infrastructure and strict validation protocols drive adoption in Germany, UK, and the Nordics.
  • Asia-Pacific – Fastest-growing region at 9.4% CAGR; China, India, and South Korea expand biomanufacturing footprint.

Major Milestones (2024–2025)

Quarter

Event

Outcome

Q1 2024

Thermo Fisher launched updated Varioskan™

Improved throughput and user interface for assay libraries

Q2 2024

Promega introduced plug-and-play injector add-on

Boosts multiplexing capabilities across oncology workflows

Q3 2024

Tecan partnered with automation integrator

Modular luminometers now part of HTS platforms

Q4 2024

BMG released new emission filter sets

Enhanced reporter gene quantification across blue-green spectrum

Q1 2025

Berthold introduced multi-plate NightSHADE variant

Bridges in vitro plate and in vivo small animal luminescence

Emerging Technologies

  • Dual-Emission Detection – Simultaneous multi-reporter quantification for pathway analysis.
  • AI-Based Assay Optimization – Software learns ideal luminescence curves and calibrations.
  • Wireless Module Integration – Seamless LIMS updates and remote assay control.
  • Eco-Friendly Design – Reagent-saving cartridges and energy-efficient electronics.

Roadmap to 2031

  • 2025 – CRO adoption of luminometer-robot hybrid stations reaches 40 %.
  • 2026 – Dual-luciferase assays become standard in GPCR-target drug screening.
  • 2027 – High-throughput luminometers with AI-assisted curve fitting widely adopted.
  • 2028 – In vivo/in vitro hybrid platforms used in 25 % of oncology pipelines.
  • 2029 – Reagent usage reduced by 30 % via smart pipetting and cartridge systems.
  • 2030 – Voice-controlled luminometers introduced in smart labs.
  • 2031 – Global installed base surpasses 150,000 units with cloud-native reporting.

For more insights, visit https://clearviewmarketinsights.com/

 

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

 

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369


Frooti 123

66 Blog posts

Comments